FB Health S.p.A.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FB Health S.p.A.
Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.
Phase III data presented in Athens shows clinical benefit for cognition and/or function in patients who are homozygous or heterozygous for the APOE4 gene.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced September through October 2013.
It's now official: the Japanese drug industry is succumbing to consolidation. The only question is whether the consolidators will be Western companies or the Japanese themselves. The latest and least unexpected transaction: Merck & Co. Inc.'s takeover of the remaining 49% of Banyu Pharmaceutical Co. Ltd. it didn't already own, in a $1.52 billion tender offer.
- OTC, Consumer
- Specialty Pharmaceuticals
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries